Fibrobiologics, inc. common stock FBLG.US Overview

BetaUS StockHealthcare
(No presentation for FBLG)

FBLG AI Analysis & Strategy

Analysis Conclusion

With insufficient quarterly financial data released by the company, we're unable to provide a rating.

FBLG Current Performance

0.05%

Fibrobiologics, inc. common stock

2.83%

Avg of Sector

-0.07%

S&P500

FBLG Key Information

FBLG Financial Forecast

Unit : USD

FBLG Earnings Table

No related data records

FBLG Profile

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Price of FBLG

FBLG FAQ

  • When is FBLG's latest earnings report released?

    The most recent financial report for Fibrobiologics, inc. common stock (FBLG) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating FBLG’s short-term business performance and financial health. For the latest updates on FBLG’s earnings releases, visit this page regularly.

  • How much debt does FBLG have?

    As of the end of the reporting period, Fibrobiologics, inc. common stock (FBLG) had total debt of 7.12M, with a debt ratio of 0.62. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company’s capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does FBLG have?

    At the end of the period, Fibrobiologics, inc. common stock (FBLG) held Total Cash and Cash Equivalents of 8.67M, accounting for 0.76 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is FBLG's EPS continuing to grow?

    According to the past four quarterly reports, Fibrobiologics, inc. common stock (FBLG)’s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of FBLG?

    Fibrobiologics, inc. common stock (FBLG)’s Free Cash Flow (FCF) for the period is -5.32M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 24.17% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.